HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Profit Tracks
Nine stock picking strategies that have crushed the market since 2001, updated every day on Zacks.com. Click Here to Learn More.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


SCR: Simcere Pharmaceutical Group - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

SIMCERE PHARMACEUTICAL GROUP (NYSE)
SCR 7.69 -0.06 (-0.77%) Vol.  51,625 16:01 ET

Day Low - High 7.63 - 7.79
52wk Low - High 4.76 - 9.98
Avg Volume 85,008
Industry MED-GENERIC DRG
Market Cap 437.08 M
Div - Yield 0.00 - 0.00
PE (forward) 16.72
PEG Ratio 1.67
Current Year Est. .46
EPS Last Year 0.55
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


upgraded 11/03/2009
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 11/04/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
SIMCERE PHARMACEUTICAL GROUP SCR PREMIUM
DOCTOR REDDYS RDY PREMIUM
PAR PHARMA COS PRX PREMIUM
HI TECH PHARMA HITK PREMIUM
See all MED-GENERIC DRG Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.33
ABR (Last Week) 2.33
# of Recs in ABR 7
Average Target Price 8.85
Industry Rank by ABR 24 out of 217
Rank in Industry 9 out of 12
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate SCR?
Buy
Sell
Find out what the Zacks Community
thinks of SCR at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR SCR
Zacks Equity Research: Report for SCR
Nov 04, 2009
Zacks Blog: Simcere’s MACD Indicates Bearishness
Oct 02, 2009
Value: Simcere Pharmaceutical Group
Nov 25, 2008
More Zacks Commentary
NEWS
Simcere Pharmaceutical Group to Announce 2009 Third Quarter Earnings on Monday, November 16, 2009
Nov 02, 2009
United States : Simcere Pharmaceutical Group Enters Agreement to Acquire a 74.49% stake in ChinaVax
Oct 31, 2009
China : Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
Oct 29, 2009
Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
Oct 29, 2009
Groundbreaking Agreement Brings OSI-930 to China
Oct 20, 2009
More News
EARNINGS ESTIMATES
  This Quarter
09/2009
Next Quarter
12/2009
This Year
12/2009
Next Year
12/2010
Average Estimate 0.09 0.12 0.46 0.60
Number of Estimates 4 4 6 5
Low Estimates 0.07 0.08 0.36 0.42
High Estimate 0.13 0.19 0.56 0.78
Year Ago EPS 0.22 0.12 0.82 0.46
EPS Growth -57.95% 2.08% -43.90% 30.43%

More Estimates

COMPANY DESCRIPTION
SIMCERE PHARMACEUTICAL GROUP is a leading manufacturer and supplier of branded generic pharmaceuticals in the rapidly growing China market. Their strategic focus is to introduce first to market generic and innovative pharmaceuticals for the treatment of diseases with high incidence and or mortality rate and for which there is a clear demand for more effective pharmacotherapy.

Full Company Report
FINANCIALS
EPS TTM .55
Sales 255.21
Net Income 33.39
Price/Earnings 13.98
Price/Book 1.44
Price/Cash Flow 7.96
Price/Sales 1.68


More Financials

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research